MEI Pharma, Inc.
(NASDAQ : MEIP)

( )
MEIP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-0.17%17.232.0%$167.83m
SAGESAGE Therapeutics, Inc.
2.44%139.799.5%$123.17m
PRGOPerrigo Co. Plc
2.30%45.906.8%$104.88m
JAZZJazz Pharmaceuticals Plc
1.32%129.072.2%$89.19m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.07%137.296.3%$77.26m
PTLAPortola Pharmaceuticals, Inc.
3.59%26.537.7%$57.20m
ICPTIntercept Pharmaceuticals, Inc.
-0.19%113.4518.6%$53.31m
AXSMAxsome Therapeutics, Inc.
-1.92%8.162.7%$45.95m
MNKMallinckrodt Plc
3.72%20.6421.1%$42.16m
CTLTCatalent Inc
1.12%35.612.4%$39.82m
ICLRICON Plc
-0.18%133.184.1%$39.17m
UTHRUnited Therapeutics Corporation
1.37%115.7514.4%$35.11m
ENDPEndo International Plc
-1.52%9.708.9%$34.69m
HZNPHorizon Pharma plc
-1.71%21.847.4%$25.74m
MDCOMedicines Company
0.25%20.0021.8%$25.48m

Company Profile

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.